Beijing Immunochina Medical Science & Technology Co., Ltd. clinical trials

A subsidiary of Imunopharm Technology Co., Ltd.

The registry lists 27 studies whose lead sponsor is Beijing Immunochina Medical Science & Technology Co., Ltd.. 10 are recruiting or about to start. Per ClinicalTrials.gov, last updated Feb 13, 2026.

Studies

Recruiting first, then most recently updated. Showing 27 of 27. All Imunopharm Technology Co., Ltd. studies →

• Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Adenocarcinoma of Gastric/Esophagogastric JunctionNot yet recruitingNCT07406984Phase 1

  Sponsor listed in the registry: Beijing Immunochina Medical Science & Technology Co., Ltd.

• Clinical Study Evaluating the Safety and Efficacy of IC19 CAR-T Cell Therapy for Refractory Systemic Lupus ErythematosusNot yet recruitingNCT06886919Early Phase 1

  Sponsor listed in the registry: Beijing Immunochina Medical Science & Technology Co., Ltd.

• Clinical Study of ZM001 Injection in the Treatment of Refractory Systemic Lupus ErythematosusNot yet recruitingNCT06852573Phase 1

  Sponsor listed in the registry: Beijing Immunochina Medical Science & Technology Co., Ltd.

• Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Colorectal CancerRecruitingNCT06718738Phase 1

  Sponsor listed in the registry: Beijing Immunochina Medical Science & Technology Co., Ltd.

• IM19 CAR-T Cell Therapy for IgA Nephropathy Patients and Membranous Nephropathy PatientsNot yet recruitingNCT06690359Early Phase 1

  Sponsor listed in the registry: Beijing Immunochina Medical Science & Technology Co., Ltd.

• WL276 CAR-T Cell Therapy for CD276 Positive Recurrent or Progressive Glioblastoma PatientsNot yet recruitingNCT06691308Early Phase 1

  Sponsor listed in the registry: Beijing Immunochina Medical Science & Technology Co., Ltd.

• IM83 Clinical Study of CAR-T Cell Therapy in Patients With Relapsed or Refractory OsteosarcomaNot yet recruitingNCT06412458Phase 1

  Sponsor listed in the registry: Beijing Immunochina Medical Science & Technology Co., Ltd.

• INS19 CAR-T Cells for the Treatment of Relapsed or Refractory Acute B Lymphoblastic LeukemiaNot yet recruitingNCT06209671Phase 1

  Sponsor listed in the registry: Beijing Immunochina Medical Science & Technology Co., Ltd.

• Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic LeukemiaNot yet recruitingNCT05309213Phase 1/2

  Sponsor listed in the registry: Beijing Immunochina Medical Science & Technology Co., Ltd.

• Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) PatientsRecruitingNCT04440436Phase 1/2

  Sponsor listed in the registry: Beijing Immunochina Medical Science & Technology Co., Ltd.

• Safety and Efficacy Evaluation of IM23 CAR-T Cells (IM23CAR-T)CompletedNCT03585517Phase 1

  Sponsor listed in the registry: Beijing Immunochina Medical Science & Technology Co., Ltd.

• Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic LeukemiaStatus unknownNCT05480501Early Phase 1

  Sponsor listed in the registry: Beijing Immunochina Medical Science & Technology Co., Ltd.

• Clinical Trial to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Multiple MyelomaStatus unknownNCT05478343Early Phase 1

  Sponsor listed in the registry: Beijing Immunochina Medical Science & Technology Co., Ltd.

• Clinical Trial to Evaluate the Safety and Efficacy of IM96 CAR-T Cells Therapy in Patients With Advanced Digestive System NeoplasmsStatus unknownNCT05287165Early Phase 1

  Sponsor listed in the registry: Beijing Immunochina Medical Science & Technology Co., Ltd.

• Clinical Trial to Evaluate the Safety and Efficacy of IM92 CAR-T Cells Therapy in Patients With Advanced Gastric or Pancreatic AdenocarcinomaStatus unknownNCT05275062Early Phase 1

  Sponsor listed in the registry: Beijing Immunochina Medical Science & Technology Co., Ltd.

• Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell LymphomaStatus unknownNCT05155215Phase 1/2

  Sponsor listed in the registry: Beijing Immunochina Medical Science & Technology Co., Ltd.

• Safety and Efficacy Evaluation of IM83 CAR-T Cells for Patients With Advanced Liver TumorsStatus unknownNCT05123209Phase 1

  Sponsor listed in the registry: Beijing Immunochina Medical Science & Technology Co., Ltd.

• Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced TumorsStatus unknownNCT05117138Phase 1/2

  Sponsor listed in the registry: Beijing Immunochina Medical Science & Technology Co., Ltd.

• Clinical Study of Intratumoral Injection of CAR-T Cells in the Treatment of Advanced Liver TumorsStatus unknownNCT04951141Early Phase 1

  Sponsor listed in the registry: Beijing Immunochina Medical Science & Technology Co., Ltd.

• Donor-derived CAR-T Cells in the Treatment of AML PatientsStatus unknownNCT04766840Phase 1

  Sponsor listed in the registry: Beijing Immunochina Medical Science & Technology Co., Ltd.

• Efficacy and Safety Evaluation of IM19 CAR-T Cell Therapy for MRD+ After TransplantationStatus unknownNCT04336501Not applicable

  Sponsor listed in the registry: Beijing Immunochina Medical Science & Technology Co., Ltd.

• Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple MyelomaStatus unknownNCT04537442Phase 1

  Sponsor listed in the registry: Beijing Immunochina Medical Science & Technology Co., Ltd.

• Safety and Efficacy Evaluation of IM19 CAR-T Cells (IM19CAR-T)CompletedNCT03173417Phase 1/2

  Sponsor listed in the registry: Beijing Immunochina Medical Science & Technology Co., Ltd.

• Assessment of Safety and Efficacy of IM19 for Relapsed or Refractory NHL PatientsStatus unknownNCT03528421Phase 1

  Sponsor listed in the registry: Beijing Immunochina Medical Science & Technology Co., Ltd.

• Safety and Efficacy Evaluation of Decitabine With R-GDPStatus unknownNCT03535753Phase 1

  Sponsor listed in the registry: Beijing Immunochina Medical Science & Technology Co., Ltd.

• Safety and Efficacy Evaluation of IM19 CAR-T CellsStatus unknownNCT03142646Phase 1/2

  Sponsor listed in the registry: Beijing Immunochina Medical Science & Technology Co., Ltd.

• Safety and Efficacy Evaluation of IM19 CellsStatus unknownNCT03344705Phase 1

  Sponsor listed in the registry: Beijing Immunochina Medical Science & Technology Co., Ltd.